Pathways of complement activation in glomerulonephritis.
D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex; D002118:Calcium / Q000378:metabolism; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins / Q000378:metabolism*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004247:DNA; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008274:Magnesium / Q000378:metabolism; D010587:Phagocytosis; D011239:Prednisolone / Q000627:therapeutic use; D011485:Protein Binding; D012075:Remission, Spontaneous
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003169:Complement Inactivator Proteins; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003165:Complement System Proteins; D004247:DNA; D011239:Prednisolone; D008274:Magnesium; D002118:Calcium